GLP-1 Weight Loss Plateau: Why It Happens

A weight loss plateau on GLP-1 medications such as Ozempic® (semaglutide) or Mounjaro® (tirzepatide) is a period of several weeks where the scale stops moving despite continued treatment. In clinical trials, semaglutide 2.4 mg produced ongoing weight loss that plateaued around week 60, while tirzepatide showed a median time to plateau of approximately 24 to 36 weeks depending on BMI category. Plateaus are a normal physiological response — not a sign that the medication has stopped working.

What causes a weight loss plateau on GLP-1 medications?

The primary driver of a weight loss plateau is metabolic adaptation, also called adaptive thermogenesis. As you lose weight, your body requires fewer calories to maintain basic functions. A 2024 study published in Obesity found that participants who lost an average of 18.4 kg experienced a reduction in resting energy expenditure of approximately 121 kcal per day beyond what would be predicted by the change in body composition alone.

In simpler terms, your body becomes more energy-efficient as it gets smaller. If you weighed 100 kg at the start of treatment and now weigh 85 kg, your body burns meaningfully fewer calories each day — both because there is less tissue to maintain and because your metabolism actively slows down in response to sustained weight loss.

A second contributing factor is hormonal. Weight loss triggers increases in hunger hormones such as ghrelin and decreases in satiety hormones such as leptin. A 2024 mathematical modeling study published in Obesity demonstrated that the timing of the weight plateau is mainly determined by how strongly the appetite feedback control circuit responds to weight loss. GLP-1 medications weaken this feedback loop, which is why they delay the plateau compared to diet alone — but they do not eliminate it entirely.

When does the plateau typically happen?

The timeline varies depending on the medication, dose, and individual factors. In the STEP 1 trial, participants taking semaglutide 2.4 mg experienced ongoing weight loss that plateaued around week 60, with a mean total weight loss of 14.9% from baseline at 68 weeks. The STEP 5 trial, which followed participants for two years, confirmed that weight loss was largely maintained after reaching a plateau, with participants sustaining approximately 15.2% weight loss at 104 weeks.

For tirzepatide, a 2025 post hoc analysis of the SURMOUNT-1 and SURMOUNT-4 trials found that the median time to weight plateau ranged from approximately 24 weeks for participants with overweight to 36 weeks for those with class II or III obesity. By week 72, roughly 88% to 90% of participants across all BMI categories had reached their weight plateau. Higher doses (10 mg and 15 mg), younger age, and female sex were associated with a later plateau.

With diet restriction alone, plateaus typically occur within 6 to 12 months and at lower total weight loss — usually 5% to 10% of starting weight. The fact that GLP-1 medications push the plateau later and to a greater degree of weight loss is one of their key clinical advantages.

Is the plateau a sign the medication stopped working?

No. A plateau does not mean your medication has stopped working. GLP-1 receptor agonists continue to act on appetite regulation, gastric emptying, and metabolic pathways even after weight loss levels off. The plateau simply reflects a new energy balance — the point at which your reduced calorie intake (driven by the medication's appetite-suppressing effects) matches your reduced calorie needs (driven by your lower body weight).

This distinction is important. The STEP 1 trial extension showed that participants who discontinued semaglutide after 68 weeks regained approximately two-thirds of the weight they had lost within one year, confirming that the medication was still actively maintaining their lower weight even during the plateau phase. In other words, the drug was working — it was preventing regain, not just driving further loss.

How does lean muscle loss contribute to the plateau?

One underappreciated factor in weight loss plateaus is the loss of lean muscle mass. Research suggests that approximately 25% to 40% of total weight lost during GLP-1 therapy comes from lean mass rather than fat. Muscle is more metabolically active than fat — it burns more calories at rest. As muscle mass decreases, resting metabolic rate drops further, which can accelerate the onset of a plateau.

A 2025 commentary published in Cell Reports Medicine highlighted that GLP-1 receptor agonist-based therapies can reduce lean muscle and energy expenditure through adaptive thermogenesis, contributing directly to weight plateaus. This is why preserving muscle through adequate protein intake and resistance training is considered one of the most important strategies during treatment.

What can you do to move past a plateau?

The most evidence-based approaches focus on protecting lean mass and supporting metabolic health rather than simply eating less. Drastically cutting calories during a plateau can actually make the problem worse by accelerating muscle loss and deepening metabolic adaptation.

Prioritize protein intake. Expert guidelines recommend consuming 1.2 to 1.6 grams of protein per kilogram of body weight per day during GLP-1 therapy. A 2025 study presented at the Endocrine Society's annual meeting found that higher protein intake was associated with significantly less muscle loss in patients taking semaglutide. When your appetite is reduced, eating protein first at each meal helps ensure you meet your daily target. For detailed guidance, see our article on how much protein you need on GLP-1.

Add or increase resistance training. Strength training at least two to three times per week helps preserve and rebuild muscle mass, which in turn supports a higher resting metabolic rate. A 2025 review in Frontiers in Clinical Diabetes and Healthcare emphasized that combining GLP-1 medications with structured exercise — particularly resistance training — can mitigate muscle loss and enhance overall weight loss outcomes.

Review your calorie intake. Some people eat too little during a plateau, which can paradoxically slow progress. The STEP and SURMOUNT trials used a 500-calorie daily deficit — not extreme restriction. If you find yourself consistently eating below 1,200 calories per day, talk to your healthcare provider. For more context, see our guide on calorie intake on GLP-1.

Discuss dose adjustment with your provider. If you have not yet reached the maximum approved dose of your medication, your healthcare provider may recommend a dose increase. Clinical trials demonstrate a clear dose-response relationship — higher doses of both semaglutide and tirzepatide produce greater weight loss. However, faster dose escalation also increases the risk of gastrointestinal side effects such as nausea and constipation, so this decision should be made carefully with your provider.

How long do weight loss plateaus usually last?

Most plateaus last between two and eight weeks, though some can persist longer — especially after significant weight loss. In the SURMOUNT-1 trial, the majority of participants who had not yet reached a clinically meaningful response (less than 5% weight loss) by week 12 still went on to achieve meaningful results by week 72. Approximately 90% of these slower responders eventually reached at least 5% total body weight loss with continued treatment.

This finding underscores the importance of patience and persistence. A plateau at any point during treatment does not predict your final outcome. Some people experience multiple shorter plateaus followed by periods of renewed weight loss as their dose increases or their body adjusts.

Should you stop taking your medication during a plateau?

No. Stopping GLP-1 medication during a plateau is likely to result in weight regain. The STEP 1 trial extension demonstrated that participants who switched from semaglutide to placebo after 68 weeks regained approximately two-thirds of their lost weight within 52 weeks. A 2025 narrative review of randomized studies confirmed that weight regain after discontinuation of liraglutide, semaglutide, or tirzepatide is a consistent finding across clinical trials.

Even during a plateau, the medication is actively suppressing appetite, slowing gastric emptying, and maintaining the metabolic changes that support your lower weight. Discontinuing treatment removes these supports and allows the body's natural drive to restore its previous weight to take over. If you are concerned about a prolonged plateau, talk to your healthcare provider about adjustments rather than stopping treatment on your own.

Can tracking your routine help during a plateau?

Yes. Tracking key data points — your weight trend over time, injection schedule, protein intake, exercise sessions, and side effects — can help both you and your healthcare provider identify patterns and make informed adjustments. A single weekly weigh-in can be misleading due to normal daily fluctuations of 1 to 2 kg from water retention, digestion, and hormonal cycles.

Looking at your weight trend over four to six weeks gives a much clearer picture of whether you are truly plateaued or simply experiencing normal variation. Glone's weight tracking and injection logging features can help you visualize these trends and bring meaningful data to your next provider appointment, making it easier to decide whether a dose adjustment or lifestyle change is warranted.

Sources

• Hall KD, Kahan S. Physiology of the weight-loss plateau in response to diet restriction, GLP-1 receptor agonism, and bariatric surgery. Obesity. 2024. — pubmed.ncbi.nlm.nih.gov
• Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. — pubmed.ncbi.nlm.nih.gov
• Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083–2091. — pmc.ncbi.nlm.nih.gov
• Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564. — pmc.ncbi.nlm.nih.gov
• Horn DB, et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clin Obes. 2025. — pubmed.ncbi.nlm.nih.gov
• Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. — pubmed.ncbi.nlm.nih.gov
• Lopez Torres O, et al. Adaptive thermogenesis at the level of resting energy expenditure after diet alone or diet plus bariatric surgery. Obesity. 2024. — pubmed.ncbi.nlm.nih.gov
• Can muscle avert GLP1R weight plateau and regain? Cell Reports Medicine. 2025. — cell.com